587 related articles for article (PubMed ID: 14502542)
1. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
2. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase.
Kim CH; Marquez VE; Mao DT; Haines DR; McCormack JJ
J Med Chem; 1986 Aug; 29(8):1374-80. PubMed ID: 3735306
[TBL] [Abstract][Full Text] [Related]
4. Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides.
Kelley JA; Driscoll JS; McCormack JJ; Roth JS; Marquez VE
J Med Chem; 1986 Nov; 29(11):2351-8. PubMed ID: 3783592
[TBL] [Abstract][Full Text] [Related]
5. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
Guo D; Myrdal PB; Karlage KL; O'Connell SP; Wissinger TJ; Tabibi SE; Yalkowsky SH
AAPS PharmSciTech; 2010 Mar; 11(1):247-52. PubMed ID: 20151336
[TBL] [Abstract][Full Text] [Related]
6. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
9. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
10. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic and kinetic study of the beta-lactone hydrolysis of Salinosporamide A (NPI-0052), a novel proteasome inhibitor.
Denora N; Potts BC; Stella VJ
J Pharm Sci; 2007 Aug; 96(8):2037-47. PubMed ID: 17554770
[TBL] [Abstract][Full Text] [Related]
12. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
13. The 1.48 A resolution crystal structure of the homotetrameric cytidine deaminase from mouse.
Teh AH; Kimura M; Yamamoto M; Tanaka N; Yamaguchi I; Kumasaka T
Biochemistry; 2006 Jun; 45(25):7825-33. PubMed ID: 16784234
[TBL] [Abstract][Full Text] [Related]
14. On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
Wentworth DF; Wolfenden R
Biochemistry; 1975 Nov; 14(23):5099-105. PubMed ID: 53069
[TBL] [Abstract][Full Text] [Related]
15. Improved synthesis of zebularine [1-(beta-D-ribofuranosyl)-dihydropyrimidin-2-one] nucleotides as inhibitors of human deoxycytidylate deaminase.
Barchi JJ; Cooney DA; Hao Z; Weinberg ZH; Taft C; Marquez VE; Ford H
J Enzyme Inhib; 1995; 9(2):147-62. PubMed ID: 8583252
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH; Eiseman JL; Gilbert JA; Holleran JL; Yellow-Duke AE; Clausen DM; D'Argenio DZ; Ames MM; Hershberger PA; Parise RA; Bai L; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2011 Feb; 67(2):421-30. PubMed ID: 20443002
[TBL] [Abstract][Full Text] [Related]
17. Flight of a cytidine deaminase complex with an imperfect transition state analogue inhibitor: mass spectrometric evidence for the presence of a trapped water molecule.
Schroeder GK; Zhou L; Snider MJ; Chen X; Wolfenden R
Biochemistry; 2012 Aug; 51(32):6476-86. PubMed ID: 22775299
[TBL] [Abstract][Full Text] [Related]
18. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Escherichia coli cytidine deaminase by a phosphapyrimidine nucleoside.
Ashley GW; Bartlett PA
J Biol Chem; 1984 Nov; 259(21):13621-7. PubMed ID: 6386818
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
